Dupixent Breakthrough: New Clinical Data Reveals Remarkable Success in Treating Atopic Dermatitis Across Skin Colors

Dupilumab improves atopic dermatitis severity in adolescents, adults with skin of color

Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), trial's primary endpoint.

Dupixent shows promise for eczema in patients with darker skin

Just over three-quarters, 76%, of patients receiving Sanofi and Regeneron’s Dupixent (dupilumab) achieved at least a 75% improvement in overall disease severity (EASI-75), the primary endpoint of the DISCOVER Phase 4 study.   The study, presented at the Revolutionizing Atopic Dermatitis Conference in Nashville, focused on patients with moderate-to-severe atopic dermatitis with skin of color.  Unmet… The post First clinical study results of Dupix…

Long-Term Study Suggests Extended Relief from Atopic Dermatitis After Topical Treatment

Data show most patients maintained mild disease for over two months without treatment following initial clearance in a 48-week extension trial. Healthcare company Organon announced results from an analysis of its Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA (tapinarof) cream, 1% once daily for treatment in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema.  The findings dem…

Regeneron and Sanofi’s dupilumab shows promise in AD trial

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).The post Regeneron and Sanofi’s dupilumab shows promise in AD trial appeared first on Clinical Trials Arena.

Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline Results support commitment to enhance clinical understanding of chronic diseases in […] The post Dupixent (dupiluma…

Dupilumab Effective in Adults, Adolescents with Skin of Color Living with Atopic Dermatitis

These late-breaking data presented at RAD 2025 highlight dupilumab’s efficacy and safety in this often neglected patient population.